Thông tin cho nhân viên y tế
Thuốc mới và thông tin từ Drugs.com
- January 12, 2026 — The U.S. Food and Drug Administration today approved the Zycubo (copper histidinate) injection as the first treatment for Menkes disease in pediatric patients. “With today’s action, children with this devastating…
- WASHINGTON, Dec. 30, 2025 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved Nereus (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the…
- SEATTLE–(BUSINESS WIRE)–Dec. 24, 2025– Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved Yartemlea (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated…
- CAMBRIDGE, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S…
- WESTLAKE VILLAGE, Calif. and BURLINGTON, Mass., December 23, 2025 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD) today announced two business updates—approval of the Furoscix (furosemide) On-body Infusor for pediatric patients and…
- On Dec. 23, 2025, the U.S. Food and Drug Administration approved Cablivi (caplacizumab-yhdp) for injection to treat pediatric patients 12 years and older with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange…
- TUESDAY, Jan. 13, 2026 — Five-year relative survival rates for all cancers combined have increased to 70 percent for people diagnosed during 2015 to 2021 in the United States, according to the Cancer Statistics, 2026, report, published online Jan…
- MONDAY, Jan. 12, 2026 — Orthopedic surgeons can play a critical role in identifying patients who have experienced intimate partner violence (IPV), according to a study recently published in JB&JS Open Access.Ophelie Lavoie-Gagne, M.D., from…
- MONDAY, Jan. 12, 2026 — Male patients with newly diagnosed multiple myeloma (MM) seem to have a higher tumor burden than female patients, with higher odds of having high serum monoclonal protein, κ light chain disease, and more end-organ…
- MONDAY, Jan. 12, 2026 — Per- and polyfluoroalkyl substance (PFAS) exposure is associated with an increased risk for metabolic dysfunction-associated steatotic liver disease (MASLD) in adolescence, according to a study published in the Jan. 1 issue…
- MONDAY, Jan. 12, 2026 — Cessation of weight management medications (WMMs) is followed by rapid weight regain and reversal of beneficial effects on cardiometabolic markers, according to a review published online Jan. 7 in The BMJ. Sam West, Ph.D…
- MONDAY, Jan. 12, 2026 — Individuals with higher than ideal body weight or body mass index (BMI) have an increased risk for low back pain (LBP), according to a study published online Dec. 19 in Pain Medicine. Michael D. Perloff, M.D., Ph.D., from…
Thông tin từ The Pharma Letter
- Germany’s Merck KGaA has announced that the US Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT).
- UK-based Nuclera, a biotech accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery System, has announced a $12 million financing extension, bringing the company’s total Series C funding to $87 million.
- UK-based Qureight, a tech-bio company advancing the understanding of lung and heart disease through application of its AI-powered CT imaging biomarkers and clinical data management platform in clinical trials, has announced the appointment of Rebecca Simmons as chief operating officer (COO).
- US pharma major AbbVie plans to acquire a drug delivery device manufacturing facility in Tempe, Arizona, as part of its $10 billion pledge to expand US operations through 2035. The site will be bought from West Pharmaceutical Services and is expected to close by mid-2026.
- The Biotechnology Innovation Organization criticized changes to the US childhood immunization schedule, saying the move lacks a scientific basis and could put children’s health at risk.
- Efforts to return to growth in UK clinical trials are gathering pace, with new figures showing a sharp rise in activity in 2025.
Thông tin từ BioPharmaDive
- Regulatory and clinical roadblocks have set back its oral BTK inhibitor tolebrutinib, but the drug class still has many opportunities to make an impact.
- As with the many other “most-favored-nation” deals between the white House and large pharmas, the agreement is short on details as well as its potential financial impact.
- Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to appease jittery investors.
- AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings target and the FDA flipped its position on a cell therapy from Atara.
- The biopharmaceutical sector finally regained its footing in 2025. Here are five issues that could determine whether the renewed optimism will carry over into the new year.
- Working towards the future of cold chain packaging: sustainable packaging without performance tradeoffs.
Thông tin từ STAT News
- In this edition of STAT Health Tech: OpenEvidence promises medical super-intelligence and other health tech news from JPM 2026.
- Epic Systems is suing Health Gorilla, a health information network, over improperly accessing nearly 300,000 patient records.
- A veteran FDA regulator who left last month said the firewall between agency political appointees and drug reviewers “has been breached"
- And other health news from the Morning Rounds newsletter
- The genomics juggernaut Illumina has launched a massive cell atlas to fast-track drug discovery.
- More people are surviving cancer than ever before, as the 5-year survival rate across cancer reached 70%, according to the American Cancer Society’s new report.
Thông tin từ Nature Review Drug Discovery
- Nature Reviews Drug Discovery, Published online: 12 January 2026; doi:10.1038/d41573-026-00006-8Nonopioid analgesic alleviates neuropathic pain
- Nature Reviews Drug Discovery, Published online: 12 January 2026; doi:10.1038/d41573-026-00003-xInnate immune receptor agonist for cancer immunotherapy
- Nature Reviews Drug Discovery, Published online: 12 January 2026; doi:10.1038/d41573-026-00005-9Boosting CAR T cell efficacy
- Nature Reviews Drug Discovery, Published online: 12 January 2026; doi:10.1038/d41573-026-00007-7Histone methyltransferase inhibition hampers prostate cancer
- Nature Reviews Drug Discovery, Published online: 12 January 2026; doi:10.1038/d41573-026-00004-wKinase inhibitors trigger target degradation
- Nature Reviews Drug Discovery, Published online: 08 January 2026; doi:10.1038/s41573-025-01335-wFor over 70 years, almost every drug approved for schizophrenia has modulated dopamine signalling, thus only addressing some symptoms and having notable side effects. Here, Coyle and Paul discuss drugs with promising new mechanisms under development for schizophrenia, including those targeting glutamatergic and cholinergic signalling.